UNSPSC 51241531: Hydroxyamphetamine/tropicamide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP600. This VA Drug Class (OP600) classifies this compound as belonging to the group MYDRIATICS/CYCLOPLEGICS, TOPICAL OPHTHALMIC.

UNSPSC 51241531 Hydroxyamphetamine/tropicamide is a Commodity code covering ophthalmic pharmaceutical products — specifically mydriatic and cycloplegic agents used in diagnostic eye examinations and clinical ophthalmology. State and local governments procure these products as part of broader pharmaceutical supply agreements for use in public health clinics, correctional health services, emergency departments, and other government-operated medical facilities. Purchasing bodies soliciting under this code include state health departments, state purchasing alliances coordinating multi-jurisdictional pharmaceutical procurement, and local public health agencies. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary recent issuer, using cooperative purchasing mechanisms to aggregate demand across participating states and localities and negotiate volume-based pricing with manufacturers and authorized wholesalers.

The Minnesota MMCAP RFP (S1070000015802), posted January 20, 2026 with proposals due March 26, 2026, exemplifies current activity under this code. MMCAP solicited multiple contracts for generic multi-source pharmaceuticals and OTC products through a Request for Proposal framework, requiring vendors to supply products through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — with contract effectiveness set for July 1, 2026. Evaluation weighted price competitiveness most heavily at 75 percent, with secondary consideration of fixed pricing structure, administrative compliance, EDI capability, and acceptance of a 3 percent administrative fee. Vendors must maintain cGMP certification and DSCSA compliance, hold active relationships with at least two of the three authorized wholesalers, and carry commercial general liability of $5 million per occurrence. The cooperative purchasing vehicle reflects the current state and local practice of aggregating specialty pharmaceutical procurement across jurisdictions to achieve cost leverage; geographic activity centers on the upper Midwest with participating states including Minnesota and Oregon.